74311429 OP Youngman : I'm taking everything into account-> But the most important thing is that this company is pretty much strong with Nexlizet and Nexletol. strong revenue growth is almost imminent, now even to a greater extent with another drug with Blockbuster potential. so my logics is as following... it's very logical and normal to see a peak of $15, possibly $20 when the company will reach $750M in revenues and constant growing of profitability (based on current shares outstanding count). and to get there seems to be natural for this company in a few years(they're growing and will grow much more with two drugs). therefore current prices are opportunity, based on the revenue stream, profitability and self sustainability going forward. I could find companies that potentially can surge even more (i have other investments), but what's unique about this company, is that they are already find their rhythm, they are big, strong, known for their brands, spread Domestically and globally successfully, while many other small caps, are not in that level of drugs that already Mega-Drugs, don’t generate $400M with real blockbuster potential (one or few), the other drug even give another boost to make everything even larger. so that's my philosophy in a nutshell.

74311429 : Wanna buy cheap

74311429 CH16 OP : I hope you've bought in a discounted price... before the surge.

74311429 CH16 OP : eventually it will rerate far higher, based on Nexlizet growth + Enbumyst. two revenue streams. of course that there was some decline as happens when a drug is purchased... but when it begins to generate revenues alongside the other drug, that combo would rerate the valuation far higher than Just the Nexlizet.

74311429 OP 103475232 : Nope. the price is very very low, in a relation to the asset worth.

74311429 : The decline is because the purchase of the new Blockbuster potential drug... when it'll begin to generate revenue, the narrative will change dramatically and the way to double digits will be paved

74311429 : This company fair Market Cap with $1B in revenues, nice profitability and self sustainability will be around $6B (I would say $10B if there were a bit higher margins). after today's addition, i believe fair timeline is 2030. fair chances of 9-10 your investment in five years with two major approved products (both blockbuster potential), is not too bad. and could be even better if you are willing to wait more. de-risked !!